In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

In-house roundup: 5G licensing challenges; second medical use solutions; PTAB tactics against NPEs; dosage regimen inventive step

effbdf

Managing IP rounds up the latest news and analysis from patent-focused businesses on 5G, the PTAB, inventive step and second medical use reform

effbdf

5G set to exacerbate FRAND problems, say top patent holders

With more diverse non-telecoms businesses using 5G tech, licensing discussions for standard essential patents are likely to increase and become more difficult to negotiate, leading patentees to promote better licensing education. Read More... 

Prescription reform needed to avoid second medical use infringement

Generic and innovator in-house lawyers agree that serious reform to the way medications are prescribed is needed to avoid patent infringement on secondary uses, and that they will need to work together to make that change. Read more... 

How tech companies use the PTAB to fight patent trolls

Senior sources from high-tech, gaming and financial services companies explain how they succeed in their inter partes reviews and covered business method actions to invalidate broad patents filed by non-practising entities. Read more... 

Inventive step: pharma innovators say "routine testing is never routine"

After the UK Supreme Court's ruling in Acatvis v Icos, pharma innovators say there is no such thing as routine testing and that it is difficult to discern what might be considered obvious in dosage regimens. Read more... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.




more from across site and SHARED ros bottom lb

More from across our site

McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks
IP firms may be growing more comfortable with external capital, but uncertainty over who could ultimately own the business is complicating the investment pitch
The former Western District of Texas judge addresses perceptions of his courtroom, reveals what comes next as he returns to practice at A&O Shearman and explains why marathon running is ‘cathartic’
International Anti-Counterfeiting Coalition says it has been blocked from hosting its annual event in the city, ending a long tradition of holding the gathering in the days leading up to INTA’s flagship event
The ITC is a powerful tool for litigators, practitioners say, as the threat of an exclusion order on a critical tech component could mean disrupting the entire data centre's operations
Anna Toh plans to expand Rajah & Tann’s soft IP capabilities, leveraging its Southeast Asia network to support clients on cross-border portfolio management and commercial strategy
The Canadian boutique’s new IP lead says he wants to build a tech-enabled IP practice aimed at giving startups senior expertise away from the traditional ‘big law’ set-up
Qantm IP’s acquisition of Henry Goh & Co shows shifting attitudes towards private equity, with firms increasingly viewing external backing as a normal route to expansion rather than a source of concern
The firm’s involvement in prominent AI cases drew litigator Christian Mammen to join from Womble Bond Dickinson, as US firms continue to bolster AI-focused practices
Two judicial appointments confirmed in Paris and Mannheim, while cross-border injunctions and high-profile procedural rulings keep major patent practices occupied
Gift this article